The antileukemic activity of the original conjugate of anthracycline antitumor antibiotic epirubicin, covalently bound to the biopolymer dextran was studied. The ascitic lymphoid leukemia L 1210 (transplantation dose 1x10 5 tumor cells/mouse, i. p.), in hybrid mice BDF 1 , was used as tumor model. An antileukemic activity of the studied original conjugate was found. The criterion "increase of life span" (ILS%) reached maximally 136,6% for the conjugate. The studied conjugate of biopolymer dextran with epirubicin showed lower toxicity but also lower antileukemic activity in comparison with free epirubicin. The further experiments in this field are in progress, aiming to design better conjugates, with potential clinical use.

No abstract

Condensation of the antitumor antibiotic carminomycin with oxidized chitosan in the presence of sodium borohydride provided a new conjugated antibiotic. A ring involving a N atom from the 3′ amino group of the antibiotic sugar moiety and the residue of the oxidized glucosamine ring of chitosan was formed during reductive alkylation. The resultant compound was characterized by IR and UV-VIS spectra which support the conjugate structure. The amount of carminomycin bound to the matrix was 25.2% w/w or 391 carminomycin residues. The biological activity of the carminomycin-chitosan conjugate showed an antibacterial action against Bacillus subtilis on the level of the initial antibiotic. Implanted lymphoid leucosis L1210 and lymphocytic leucosis P388 in hybrid mice BDF1 showed: a T/C = 242.9 (P388) (for free carminomycin T/C = 177.9%) and a T/C = 201.4 (L1210) (for the free drug T/C = 179.85%).

No abstract

No abstract